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Abstract Changes in expression of calpains and calpastatin during differentiation in GOTO cells were examined using antibodies specific to calpains 
and calpastatin. Neuronal differentiation induced by dibutyryl cyclic AMP elicited a remarkable decrease in m-calpain. No marked changes in the 
levels of calpains were found in bromodeoxyuridine-indueed Schwannian differentiation. Calpastatin was detected asa single band of ll0k in 
undifferentiated and in neuronally differentiated cells by Western blot analysis. However, the appearance of a 120k species was detected inSchwannian 
differentiation associated with morphological change. The data show that marked changes in m-calpain and calpastatin occur in a differentiation- 
specific manner. 
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1. Introduction 
Proteases have been implicated to be involved in various 
stages of neuronal development including glial proliferation, 
cell migration, and neurite outgrowth [1-3]. Many studies on 
calpains have been performed in the nervous ystem [4-10], but 
little is known about the roles of calpains in neuronal differen- 
tiation. In rat pheochromocytoma PC12 cells, cell-permeable 
calpain inhibitors cause initiation of neurite outgrowth without 
nerve growth factor (NGF) [11], and a relative decrease in 
calpain activity caused by an increase in calpastatin activity was 
observed uring NGF-induced neurite outgrowth [12]. These 
results dearly suggest hat the calpain--calpastatin system is 
associated with the neuronal differentiation process in the 
NGF-responsive PC12 cell line. It is not clear, however, 
whether quantitative and qualitative changes in calpains and 
calpastatin occur during neuronal differentiation of other cell 
lines and during other types of differentiation. 
A human neuroblastoma cell line, GOTO, derived from ad- 
renal gland tumors, has bipotential characteristics in differenti- 
ation; that is, treatment with bromodeoxyuridine (BrDU) 
causes the cells to differentiate into Schwannian cells [13,14], 
while withdrawal of serum from the culture medium induces 
neurite outgrowth and increases the level of neurofilament pro- 
tein mRNA [15]. Thus, GOTO cells provide an attractive model 
system for studying the molecular details of Schwannian/neu- 
ronal cell differentiation. Since Schwannian/neuronal differen- 
tiation induced from precursor cells is accompanied by turno- 
ver of and profound changes in membrane proteins and 
cytoskeleton proteins which are the preferable substrates of 
calpain, we expected that the calpain-calpastatin system might 
be involved differently in each developmental pathway. To 
approach to this problem, we examined changes in the levels 
of m-calpain,/z-calpain, and calpastatin during Schwannian/ 
neuronal differentiation i GOTO cells using specific antibod- 
ies to human calpains and calpastatin. The results ' show that 
there was a marked decrease in the level of m-ealpain during 
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neuronal differentiation, while a new species of calpastatin ap- 
peared uring Schwannian differentiation. 
2. Experimental 
2.1. Materials 
Antibodies pecific to human m-calpain and/z-calpain 80k subunits 
were produced as described [16]. Monoclonal antibodies specific to 
human calpastatin were from Takara (Tokyo, Japan). RPMI 1640 
medium was from Gibco (Grand Island, NY). Fetal bovine serum 
(FBS) was from Cell Culture Laboratories (Cleveland, OH). Collagen 
type IV (0.3% solution in 1 mM HC1) derived from bovine placenta was 
obtained from Koken (Tokyo, Japan). Dibutyryl cyclic AMP 
(dbcAMP) was obtained from Yamasa (Chiba, Japan). Collagen type 
I-coated ishes were purchased from Coming. All unspecified chemi- 
cals were of analytical grade, and purchased either from Wako Pure 
Chemicals, Nacalai Tesque, or Sigma. 
2.2. Cell culture 
GOTO cells were cultured in RPMI medium supplemented with 10% 
FBS, 100 U/ml potassium penicillin G, and 100/zg/ml streptomycin in 
a humidified atmosphere of 95% air and 5% CO2 on collagen type 
I-coated ishes. 
2.3. Differentiation 
Schwannian differentiation. Cells were plated at 1 x 104 cells/era 2 on 
collagen type-I coated ishes. After 24 h incubation, cells were main- 
tained in the medium with or without 5/zg/ml BrDU for 16 days with 
a change of medium every 72 h. 
Neuronal differentiation. 0.1% solution of collagen type IV solution 
in 1 mM HC1 derived from bovine placenta was spread as a film over 
the dish and allowed to dry at room temperature under ultraviolet 
irradiation for 1 h. Cells were plated at 0.25 x 104 cells/em 2 on collagen 
type-IV coated dishes. After 24 h incubation, the medium was changed to 
fresh N2 medium and dibutyryl cyclic AMP (dbeAMP) was added at a 
concentration f 1 mM. N2 medium consists of the DMEM/Ham's F12 
(1:1) base medium supplemented with 25 mM HEPES, 5/zg/ml insulin, 
50/zg/ml transferrin, 5/tg/ml putrescine, 5/zg/ml progesterone, and 52
/zg/ml sodium selenite. The medium was changed every other day. 
2.4. Preparation f cell homogenates and subcellular fractions 
All experimental operations were performed on ice. Cells were col- 
lected by centrifugation i  phosphate-buffered saline (PBS) without 
Ca 2* and Mg 3+ and washed twice with PBS. Cells were disrupted in a 
tightly fitting Dounce homogenizer in homogenizing buffer (100 mM 
sodium phosphate, 150 mM NaCI, 2 mM EDTA, 2 mM EGTA, 100 
/zM phenylmethanesulfonyl fluoride, 100 /~M diisopropyl fluoro- 
phosphate, 50/zM leupeptin, pH 7.2) until the nuclei became micro- 
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scopically free. The homogenate was then ultracentrifuged at 
100,000 x g for 60 rain. The supernatants and the pelleted debris were 
termed the cytoplasmic fraction and membrane fraction, respectively. 
Nuclei were contained in the membrane fraction. 
2.5. lmmunoblot analysis 
Ceil homogenates prepared as described above were subjected to 
SDS-polyacrylamide gelelectrophoresis and transferred to nylon mem- 
branes. The membranes were treated with polyclonal antibodies specific 
Fig. 1. Morphological ppearance of the human neuroblastoma cell line GOTO. GOTO ceils were cultured in the presence of (A) serum-containing 
growth medium, (B) 5/lg/ml BrDU for 2 days, (C) 5/~g/ml BrDU for 5 days, (D) 1 mM dbcAMP/N2 medium for 3 days, or (E) 1 mM dbcAMP/N2 
medium for 6 days. Ceils were photographed using an invert, phase-contrast microscope, x 200. 
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for the 80k subunit of human m-calpain or p-calpain or a monoclonal 
antibody to human calpastatin domain III for 3 h at 37°C, and sub- 
jetted to alkaline phosphatase staining. In some experiments, monoclo- 
nal antibodies tohuman calpastatin domains I and IV were used. The 
bands on the membranes were quantitated with a densitometer (ACI 
Japan. Digitizer 256). 
3. Results 
3.1. Morphological changes in GOTO cells 
GOTO cells were small and spindle-shaped cells in serum- 
containing medium (Fig. 1A). Two days after treatment with 
BrDU, the cells began to enlarge and flatten, and possesed 
polygonal cytoplasm that adhered firmly to the substrate (Fig. 
1B,C). GOTO cells grew slowly from 2 days and reached only 
15% of control cells 7 days after treatment with BrDU. The 
viability of the BrDU-treated GOTO cells was 87.5 + 3.4% 
(S.D.) during the period. It has been reported that BrDU in- 
duces an increase in the amount of S100 protein [13,14] and in 
the activity of cyclic nucleotide phosphodiesterase (CNPase) 
[13] in GOTO cells, suggesting that BrDU-treated GOTO cells 
have Schwannian characteristics. On the other hand, using a 
substratum coated with purified collagen type IV, N2 medium 
with dbcAMP induced the formation of large cellular aggre- 
gates (pseudoganglia) until 3 days (Fig. 1D). After the forma- 
tion of cellular aggregates, the cells began to initiate neurite 
outgrowth, and finally the aggregates were interconnected by 
long neurites over 6 days (Fig. 1E). 
3.2. Changes in ealpain levels in GOTO cells during 
differentiation 
Changes in the levels of m- and g-calpains during Schwan- 
nian and neuronal differentiation detected by Western blot 
A 
analysis are shown in Fig. 2. Schwannian differentiation i - 
duced by BrDU in GOTO cells caused a slight increase in the 
level of p-calpain at 5 days (Fig. 2A), which returned to the 
original evel after 16 days (data not shown). In contrast, neu- 
ronal differentiation i duced by treatment with N2 medium/ 
dbcAMP for 6 days caused a remarkable decrease in m-calpain 
immunoreactivity (Fig. 2A). Fig. 2B shows the time course for 
the change in the level of m-calpain using Western blot analysis. 
The bands on the membranes were quantitated by evaluating 
the stained area with a densitometer and expressed as the rela- 
tive intensities to 0 day (100%). Areas under peaks were 101% 
after 2 days, 77% after 3 days, 67% after 4 days, 53% after 
5 days, and 30% after 6 days. The change shows that the 
decrease in m-calpain is not associated with cellular aggrega- 
tion occurring up to 2 days, but rather with the beginning of 
neurite formation starting at 4 days. The cells seeded on colla- 
gen type IV-coated dishes under serum-containing conditions 
showed no change in immunoreactivity to either anti-m-calpain 
or anti-g-calpain over a period of 6 days. 
3.3. Changes in calpastatin levels in GOTO cells during 
differentiation 
To examine whether the decrease in m-calpain is accompa- 
nied by a change in calpastatin, calpastatin levels were analyzed 
by Western blot using an antibody specific to human calpas- 
tatin domain III. In non-treated GOTO cells, a single band of 
110k calpastatin was detected. During neuronal differentiation, 
there was no substantial quantitative or qualitative change for 
6 days in calpastatin after treatment with serum-free N2 me- 
dium/dbcAMP (Fig. 3A). Interestingly, however, Schwannian 
differentiation i duced by BrDU for 5 days caused the appear- 
ance of a new form, 120k calpastatin (Fig. 3A). We next exam- 
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Fig. 2. Effect of BrDU or dbcAMP/N2 on the level of the calpalns in GOTO cells as determined by immtmoblotting. (A) GOTO cells were treated 
with 5 pg/mi BrDU for 5 days or lmM dbcAMP/N2 medium for 6 days. The proteins (30pg) from whole cells were separated on 10% SDS- 
polyacrylamide gels and transferred electrophoretically o nylon membranes. The membranes were treated with polyclonal antibodies specific to the 
80k subunit of human m-, or p-calpaln and subjected to alkaline phosphatase staining. (B) GOTO cells were treated with 1 mM dbeAMP/N2 medium 
for the indicated number of days. Thirty micrograms of protein from whole cells on each day were subjected to 10% SDS-polyacrylamide gel 
electrophoresis followed by immunoblotting. The nylon membranes were treated with m-calpain-specific antibody. 
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Fig. 3. Western blot analysis of calpastatin GOTO cells after treat- 
merit with BrDU or dbcAMP/N2 medium. (A) GOTO cells were cul- 
tured in serum-containing growth medium for 6 days (lane 1), with 
1 mM dbcAMP/N2 medium for 6 days (lane 2), or with 5/zg/ml BrDU 
for 5 days (lane 3). Thirty micrograms of Wotein from whole cells were 
subjected to 7.5% SDS-polyacrylamide gel lectrophoresis followed by 
immunoblotting. The nylone membranes were treated with monoclonal 
antibody to human calpastatin domain III. (B) GOTO cells were cul- 
tured in the presence of 5 pg/ml BrDU for the indicated number of days. 
Proteins from whole cells were analyzed as described in (A). (C) GOTO 
cells were collected and separated into fractions of cytoplasm (s) and 
membranes (p) after treatment with 5 pg/ml BrDU for 5 days. Each 
fraction was subjected to immunoblotting using antibodies t  human 
calpastatin domains I, III and IV. 
ined time-dependent changes in calpastatin during Schwannian 
differentiation i GOTO cells. The appearance of 120k calpas- 
tatin was noted faintly at 1 day. Its level reached a peak after 
2 days, and this level remained unchanged uring 16 days of 
treatment with BrDU (Fig. 3B). The subcellular localization of 
calpastatin is shown in Fig. 3C. Nearly all l l0k and 120k 
calpastatins were located in the cytosol, and these calpastatins 
were recognized not only with an antibody against domain III 
but also with antibodies against domain I and IV (Fig. 3C). 
Immunocytochemical studies of GOTO ceils in serum-contain- 
ing medium showed that these calpastatins were distributed 
diffusely in the cytoplasm, but not in membranes nor nuclei; a 
more intense but similar staining pattern was observed in cells 
after treatment with BrDU for 5 days (data not shown). 
4. Discussion 
Using the combination of a bipotent differentiating model, 
GOTO, and antibodies pecific to human calpains and calpas- 
tatin, we have demonstrated that the dynamic hanges in the 
calpain-calpastatin system occur in a differentiation-specific 
mannner. 
4.1. Neuronal differentiation i GOTO cells 
During neuronal differentiation, the amounts of m-calpain 
markedly decreased. Since the change in the level in calpastatin 
was insignificant during neuronal differentiation, simple calcu- 
lation would result in a decrease in net calpain activity. The 
decrease in the m-calpain level is not associated with cellular 
aggregation but rather with neurite outgrowth. Oshima et al. 
presented evidence that NGF causes a decrease in the activity 
of calpain in morphologically differentiating PC12 cells [12]. In 
our preliminary experiment, a functional calpastatin peptide 
caused an increase in the number and length of neurites when 
added together with dbcAMP/N2 medium in GOTO cells. 
These results suggest that the decrease in calpain activity may 
be directly related to neurite outgrowth, possibly by controlling 
available soluble pools of substrates uch as cytoskeleton 
[12,17]. However, in PC12 cells, the decrease in calpain activity 
is not due to a decrease in calpain itself, but to an increase in 
the activity of calpastatin. Differences in the mechanisms for 
the relative decrease in calpain activity might reflect differences 
in neuronal cell types or in the pathway for neurite outgrowth; 
dbcAMP/N2 induces the formation of pseudoganglia and fi- 
nally the aggregates are interconnected by long neurites in 
GOTO cells, while NGF induces two or three neurites from a 
single cell body leading finally to a complex branchipg pattern 
in PCI2 cells. 
The decrease in the amount of m-calpain leads neuronally- 
differentiated GOTO cells to be richer in p-calpain than in 
m-calpain. This result obtained in cultured cells is consistent 
with many immunohistochemical studies in nervous tissue; that 
is, /z-calpain is found predominantly in neuronal perikarya 
rather than in glia [5-7]. Developmental switching of m-calpain 
in GOTO cells also corresponds well with the immunohisto- 
chemical observation reported by Hamakubo et al. [5] that 
m-calpain disappears in neuronal cells during rat brain devel- 
opment. Differences in the developmental pathways uggest 
differences in physiological function between calpain species, 
and it seems likely that/z-calpain plays a crucial role in neuronal 
cell function. 
4.2. Schwannian differentiation i GOTO cells 
During Schwannian differentiation, o dramatic change in 
calpains was observed, however, heterogeneity in calpastatin 
(11 Ok and 120k) was detected by immunoblotting. Of particular 
interest is our observation that the appearance ofthe 120k form 
is characteristic for Schwannian differentiation and not de- 
tected in neuronal differentiation ofGOTO cells and SH-SY5Y 
cells (data not shown). We confirmed that an increase in the 
immunoreactivity of S100~tfl protein was not noted until 2 days 
of BrDU treatment, and intense staining was detected after 
5 days (data not shown). These results how that the change in 
calpastatin is associated with cell flattening (Fig. 1B) but not 
with Sl00ctfl protein expression. 
The molecular diversity of calpastatin has been reported in 
other tissues and cell lines [18-22], but the present study is the 
first in which calpastatin heterogeneity is observed uring dif- 
ferentiation at the cellular level. The brain has been found to 
contain two calpain-specific inhibitory fractions, CS-0.1, identi- 
fied as an ordinary calpastatin, and CS-0.2, which has been only 
partially purified [18]. Interestingly, these fractions how devel- 
opmental variations in postnatal mouse brain [23]. Since CS-0.2 
contains proteins smaller than l l0k and does not crossreact 
with polydonal and monodonal anti-calpastatin antibodies, 
neither 110k nor 120k calpastatin i  GOTO cells corresponds 
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to CS-0.2. The diversity of calpastatin is generated whether at 
the posttranscriptional stage by exon skipping in domains L 
and I [20,22] or at the posttranslational stage, including prote- 
olytic processing for erythrocyte ealpastatin [20] and phospho- 
rylation [21]. The microheterogeneity of calpastatin (116k and 
118k), as labeled metabolically with 32p in hematopoietic cell 
lines, was reported by Adachi et al. [21]. They showed that more 
than 30% of phosphorylated calpastatins were distributed in the 
membrane fraction. Since both the l l0k and 120k species in 
GOTO cells are localized in the cytosol fraction, it seems un- 
likely that the diversity is mainly caused by phosphorylation. 
Experiments are now underway in our labolatory to elucidate 
the molecular basis for 110k and 120k heterogeneity. Whatever 
the nature of 110k and 120k, it is important to note that 120k 
calapstatin is closely associated with the acquisition of the 
Schwannian phenotype in neuroblastoma cells. 
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